Sort
50,496 grants matching “lung cancer”
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
$624,529Jia Wu · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Multi-Pathway DNA Repair Capacity Measurements in Lung Cancer Patients and Healthy Controls
$624,480Zachary David Nagel · Harvard School Of Public Health · U01 · FY2020 · ES
Development of Drugs Acting at Adenosine Receptors
$624,412Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Integrated omics analysis of clonal hematopoiesis and cardiovascular disease risk in TOPMed
$624,385Karen Conneely · Emory University · R01 · FY2024 · HL
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
$624,332Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Basic applications for total-body PET in oncology
$624,292Lorenzo Nardo · University Of California At Davis · R01 · FY2019 · CA
Epigenetic Alterations Induced by Tobacco Smoke
$624,166David Schrump · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Epidemiologic Architedure of Lung Cancer and Smoking
$624,146Christopher I. Amos · Dartmouth College · U19 · FY2012 · CA
Natural Products with Selective Cytoxicity to Non Small Cell Lung Cancer
$624,106John D Minna · Ut Southwestern Medical Center · R01 · FY2018 · CA
Core B: Clinical Core
$624,076Joel L Weissfeld · University Of Pittsburgh At Pittsburgh · P50 · FY2013 · CA
Gefitinib-sensitive EGF receptor mutants in lung cancer
$624,020Jeffrey E Settleman · Massachusetts General Hospital · R01 · FY2008 · CA
VAULT NANOPARTICLE IMMUNOTHERAPY FOR LUNG CANCER
$624,000University Of California, Los Angeles · · FY2018 · Department of the Army
Development of Pirenzepine for CIPN
$623,955Andrew Mizisin · Winsantor, Inc. · R42 · FY2018 · CA
THERAPEUTICALLY TARGETING MITOCHONDRIA BIOENERGETICS IN IMMUNE-COLD NON-SMALL CELL LUNG CANCER
$623,816University Of California, Los Angeles · · FY2020 · Department of the Army
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
$623,787Paul E Kinahan · University Of Washington · U24 · FY2022 · CA
ASPH Targeted Therapy for Chondrosarcoma
$623,782Richard M Terek · Rhode Island Hospital · R01 · FY2024 · CA
PET Imaging of KRAS2 Activation to Guide EGFR Targeting in Cancer Therapy
$623,627Eric Wickstrom · Thomas Jefferson University · R01 · FY2010 · CA
Understanding determinants of racial disparities in lung cancer incidence
$623,587Melinda Aldrich · Vanderbilt University Medical Center · U01 · FY2022 · CA
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$623,527Edward B Garon · University Of California Los Angeles · R01 · FY2025 · CA
Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients
$623,513Matthew B Weinger · Vanderbilt University Medical Center · R18 · FY2019 · HS
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer
$623,508Peter Kent Jackson · Stanford University · U01 · FY2018 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer
$623,472Paul Tempst · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer
$623,472Paul Tempst · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
GENETIC EPIDEMIOLOGY OF LUNG CANCER
$623,451Wayne State University · R01 · FY2001 · CA
Residential radon exposure and stroke risk: the REGARDS study
$623,279Ka He · Columbia University Health Sciences · R01 · FY2022 · NS